• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在多重耐药菌背景下,匹美西林在治疗尿路感染中的新兴临床作用。

Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria.

机构信息

Department of Microbiology, Sunderland Royal Hospital, Kayll Road, Sunderland SR4 7TP, UK.

出版信息

J Antimicrob Chemother. 2014 Feb;69(2):303-8. doi: 10.1093/jac/dkt368. Epub 2013 Sep 25.

DOI:10.1093/jac/dkt368
PMID:24068280
Abstract

The continuing spread of resistant Gram-negative bacteria is a therapeutic challenge and prudent use of antimicrobials is therefore essential. Urinary tract infections (UTIs), usually due to Gram-negative bacteria, are among the most common infections seen in the community. Moreover, bacterial strains producing extended-spectrum β-lactamases (ESBLs) that are resistant not only to cephalosporins and penicillins, but also to fluoroquinolones and trimethoprim, are becoming more prevalent in the community. This means that oral antibiotic options to treat these infections are limited. The discovery of new drugs to tackle these problems has been difficult and slow paced; it is therefore timely to 'rediscover' the current antibiotics we have available in our clinical formulary, to determine how best they can be used. Pivmecillinam is an oral antibiotic with excellent clinical efficacy in the treatment of uncomplicated UTIs. It has been used extensively in Nordic countries with few problems, but, despite this, it is not widely used in other countries. There is emerging in vitro and in vivo evidence of its activity against ESBL-producing organisms and its synergistic potential with β-lactamase inhibitors. Pivmecillinam is well tolerated with a low side-effect profile. Pivmecillinam also has a minimal effect on the intestinal and vaginal flora of the host; thus, there is a lower rate of selection of resistant bacteria, vaginal candidiasis and, of note, Clostridium difficile.

摘要

耐药革兰氏阴性菌的持续传播是一个治疗挑战,因此谨慎使用抗生素至关重要。尿路感染(UTIs)通常由革兰氏阴性菌引起,是社区中最常见的感染之一。此外,产生扩展谱β-内酰胺酶(ESBLs)的细菌菌株不仅对头孢菌素和青霉素耐药,而且对氟喹诺酮类和甲氧苄啶耐药,在社区中越来越普遍。这意味着治疗这些感染的口服抗生素选择有限。发现新的药物来解决这些问题一直很困难且进展缓慢;因此,及时“重新发现”我们临床处方中现有的抗生素,以确定如何最好地使用它们是很重要的。匹美西林是一种治疗单纯性尿路感染具有极好临床疗效的口服抗生素。它在北欧国家被广泛使用,几乎没有问题,但尽管如此,它在其他国家并没有被广泛使用。越来越多的体外和体内证据表明它对产 ESBL 生物体具有活性,并且与β-内酰胺酶抑制剂具有协同作用。匹美西林具有良好的耐受性,副作用发生率低。匹美西林对宿主的肠道和阴道菌群也几乎没有影响;因此,耐药菌、阴道念珠菌的选择率较低,值得注意的是,艰难梭菌的选择率也较低。

相似文献

1
Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria.在多重耐药菌背景下,匹美西林在治疗尿路感染中的新兴临床作用。
J Antimicrob Chemother. 2014 Feb;69(2):303-8. doi: 10.1093/jac/dkt368. Epub 2013 Sep 25.
2
Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.抗菌药物耐药性和新型抗菌药物时代的尿路感染治疗。
Postgrad Med. 2020 Apr;132(3):234-250. doi: 10.1080/00325481.2019.1680052. Epub 2019 Oct 24.
3
Pivmecillinam--therapy of choice for lower urinary tract infection.匹美西林——下尿路感染的首选治疗药物。
Int J Antimicrob Agents. 2003 Oct;22 Suppl 2:73-8. doi: 10.1016/s0924-8579(03)00235-8.
4
Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: a prospective, multicentre, observational cohort study.产 ESBL 大肠埃希菌引起的单纯性尿路感染采用匹美西林治疗的临床和细菌学疗效:一项前瞻性、多中心、观察性队列研究。
J Antimicrob Chemother. 2018 Sep 1;73(9):2503-2509. doi: 10.1093/jac/dky230.
5
Pivmecillinam for the treatment of acute uncomplicated urinary infection.匹美西林治疗急性单纯性泌尿系统感染。
Int J Clin Pract. 1999 Dec;53(8):612-7.
6
Effect on the human normal microflora of oral antibiotics for treatment of urinary tract infections.口服抗生素治疗尿路感染对人体正常微生物群的影响。
J Antimicrob Chemother. 2000 Sep;46 Suppl 1:41-8; discussion 63-5.
7
Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region.亚太地区复杂性尿路感染的流行病学和适当抗菌治疗的共识综述。
J Infect. 2011 Aug;63(2):114-23. doi: 10.1016/j.jinf.2011.05.015. Epub 2011 Jun 12.
8
Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in Antananarivo, Madagascar.马达加斯加塔那那利佛地区引起社区获得性尿路感染的尿路病原菌的耐药性。
J Antimicrob Chemother. 2007 Feb;59(2):309-12. doi: 10.1093/jac/dkl466. Epub 2006 Nov 29.
9
Pivmecillinam versus sulfamethizole for short-term treatment of uncomplicated acute cystitis in general practice: a randomized controlled trial.匹美西林与磺胺甲噻二唑用于全科医疗中单纯性急性膀胱炎的短期治疗:一项随机对照试验。
Scand J Prim Health Care. 2009;27(1):6-11. doi: 10.1080/02813430802535312.
10
In-vitro sensitivity of organisms causing urinary tract infections to four common oral antibiotics and to pivmecillinam.引起尿路感染的微生物对四种常见口服抗生素及匹美西林的体外敏感性
West Indian Med J. 1988 Dec;37(4):201-4.

引用本文的文献

1
New Perspectives on Antimicrobial Agents: Pivmecillinam.抗菌药物的新视角:匹美西林
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0182424. doi: 10.1128/aac.01824-24. Epub 2025 Jul 21.
2
Similarities in the consumption trajectory of antibacterial drugs in the outpatient care sector in Germany from 1986 to 2022: identification of shared patterns, correlation analysis of prescribed defined daily dose and assessment of underlying influences.1986年至2022年德国门诊护理部门抗菌药物消费轨迹的相似性:共享模式的识别、规定日剂量的相关性分析及潜在影响评估
Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr 23. doi: 10.1007/s00210-025-04165-0.
3
Performance of disc diffusion and four commercially available MIC tests to determine mecillinam susceptibility on carbapenemase-producing Enterobacterales.
纸片扩散法和四种市售最小抑菌浓度(MIC)检测方法对产碳青霉烯酶肠杆菌科细菌美西林敏感性的检测性能
J Clin Microbiol. 2025 May 14;63(5):e0147324. doi: 10.1128/jcm.01473-24. Epub 2025 Apr 14.
4
Mecillinam activity against multidrug-resistant and .美西林对多重耐药菌的活性以及……(原文不完整)
Microbiol Spectr. 2025 Mar 4;13(3):e0100624. doi: 10.1128/spectrum.01006-24. Epub 2025 Feb 7.
5
Prevalence and risk factors of extended-spectrum beta-lactamase producing E. coli causing urinary tract infections in Iceland during 2012-2021.2012-2021 年冰岛产超广谱β-内酰胺酶大肠埃希菌引起尿路感染的流行状况及危险因素分析。
Eur J Clin Microbiol Infect Dis. 2024 Sep;43(9):1689-1697. doi: 10.1007/s10096-024-04882-z. Epub 2024 Jun 27.
6
Antimicrobial Activity of Gepotidacin Tested against Escherichia coli and Staphylococcus saprophyticus Isolates Causing Urinary Tract Infections in Medical Centers Worldwide (2019 to 2020).抗微生物活性 gepotidacin 测试对造成尿路感染的大肠杆菌和腐生葡萄球菌的分离株在世界各地的医疗中心 (2019 年至 2020 年)。
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0152522. doi: 10.1128/aac.01525-22. Epub 2023 Mar 6.
7
Pharmacokinetic/Pharmacodynamic Determination of Systemic MIC Breakpoints for Intermittent, Extended, and Continuous Infusion Dosage Regimens of Mecillinam.美西林间歇、延长和持续输注给药方案的全身最低抑菌浓度(MIC)断点的药代动力学/药效学测定
Microbiol Spectr. 2023 Jan 30;11(2):e0344122. doi: 10.1128/spectrum.03441-22.
8
Assessing Clinical Potential of Old Antibiotics against Severe Infections by Multi-Drug-Resistant Gram-Negative Bacteria Using In Silico Modelling.利用计算机模拟评估旧抗生素对多重耐药革兰氏阴性菌所致严重感染的临床潜力
Pharmaceuticals (Basel). 2022 Nov 30;15(12):1501. doi: 10.3390/ph15121501.
9
Reviving the role of mecillinam against extended spectrum beta-lactamase producing enterobacterales.恢复美西林对产超广谱β-内酰胺酶肠杆菌科细菌的作用。
Iran J Microbiol. 2022 Oct;14(5):662-668. doi: 10.18502/ijm.v14i5.10959.
10
Activity of mecillinam against carbapenem-resistant Enterobacterales.美西林对碳青霉烯类耐药肠杆菌科的活性。
J Antimicrob Chemother. 2022 Sep 30;77(10):2835-2839. doi: 10.1093/jac/dkac226.